Transaction · 0002048588-26-000002

Feider Stephen

Feider Stephen, CFO, reported an open-market or private sale at Beta Bionics, Inc. involving 20000.000000 shares for an estimated $590680.00. Reported holdings after the transaction were 42614.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
BBNXBeta Bionics, Inc.
Filing timeJan 05
Trade dateJan 02, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$29.25
Pre-filing
1mo ago +1.0%1w ago +1.0%1d ago +1.0%
Returns since
7d +0.0%30d -53.2%90d -65.8%180d -42.7%1y -32.6%

BBNX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
BBNX since 2026-01-05Filed 242 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0002048588-26-000002
Common Stock
Transaction date
Jan 02, 2026
Filed Jan 05, 2026, 11:03 PM · 3d delay
Shares
20.0k sh
$2.95k per share
Estimated value
-$59.0M
Computed from shares × price
Holdings after
42.6k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Large Holdings Reduction 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

  2. F2

    The weighted average sale price for the transaction reported was $29.534002 and the range of prices were between $29.09 and $30.06. Upon request by the SEC staff, the Issuer, or any security holder of…

  3. F3

    The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

Original filing · 0002048588-26-000002
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

BBNX